BRAIN RELAPSE IN HER2-POSITIVE BREAST CANCER AFTER NEOADJUVANT TREATMENT: AN INTERNATIONAL MULTICENTRIC STUDY

被引：1

作者：

Fortuna, A. ^{[1
]}

Nobre Carvalho, A. ^{[2
]}

Soares de Pinho, I. ^{[3
]}

Lopes-Bras, R. ^{[3
]}

Patel, V. ^{[3
]}

Esperanca-Martins, M. ^{[3
]}

Goncalves, L. ^{[3
]}

Freitas, R. ^{[4
]}

Simao, D. ^{[5
]}

Roldan Galnares, M. ^{[6
]}

Fernandes, I. ^{[7
]}

Artacho Criado, S. ^{[6
]}

Gamez Casado, S. ^{[8
]}

Baena Canada, J. ^{[8
]}

Saffie Vega, I. M. ^{[9
]}

Costa, J. ^{[10
]}

Fernandes, A. S. ^{[10
]}

Teixeira de Sousa, R. ^{[3
]}

Costa, L. ^{[3
]}

Luz, P. ^{[1
,10
,11
]}

机构：

[1] Ctr Hosp Univ Algarve, Faro, Portugal

[2] Ctr Hosp Entre Douro e Vouga, Med Oncol, EPE, Santa Maria, RS, Portugal

[3] Hosp Santa Maria, CHULN, Med Oncol Dept, Lisbon, Portugal

[4] Hosp Prof Dr Fernando Fonseca, Med Oncol Dept, Amadora, Portugal

[5] Ctr Hosp Lisboa Cent, Med Oncol Dept, Lisbon, Portugal

[6] Hosp Virgen de Valme, Pharma Dept, Seville, Spain

[7] Ctr Hosp Barreiro Montijo, Med Oncol Dept, Barreiro, Portugal

[8] Hosp Univ Puerta del Mar, Med Oncol Dept, Cadiz, Spain

[9] Fdn Arturo Lopez Perez, Unidad Cirugia Oncol & Reconstructiva Mamaria, Providencia, Chile

[10] CBIOS Univ Lusofonas Res Ctr Biosci & Hlth Techno, Lisbon, Portugal

[11] Univ Alcala, Dept Biomed Sci, Madrid, Spain

来源：

NEURO-ONCOLOGY | 2023年 / 25卷

关键词：

D O I：

10.1093/neuonc/noad137.288

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P11.54.A

引用

页数：1

共 50 条

[31] Progression and treatment of HER2-positive breast cancer
Davoli, April
Hocevar, Barbara A.
Brown, Thomas L.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 611 - 623
[32] The Adjuvant Treatment of HER2-Positive Breast Cancer
Jelovac, Danijela
Wolff, Antonio C.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (02) : 230 - 239
[33] Treatment strategy for HER2-positive breast cancer
Hirofumi Mukai
International Journal of Clinical Oncology, 2010, 15 : 335 - 340
[34] INDIVIDUALIZED TREATMENT FOR HER2-POSITIVE BREAST CANCER
Takano, Toshimi
ANNALS OF ONCOLOGY, 2014, 25
[35] Influencing factors of the recurrence after neoadjuvant therapy in HER2-positive breast cancer.
Murillo, Serafin Morales
Ariadna, Gasol Cud S.
Der-Abrain, Noemi Tuset
Rodriguez, Alvaro
Sanchez, Ana Velasco
Vilardell, Felip
Guzman, Douglas Sanchez
Morales, Carles Canosa
Olive, Jordi Mele
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[36] Prognostic implications of HER2 change after neoadjuvant chemotherapy in HER2-positive breast cancer patients
Sato, A.
Maeda, Y.
Matsumoto, A.
Ikeda, T.
Jinno, H.
ANNALS OF ONCOLOGY, 2024, 35 : S1409 - S1409
[37] Neratinib in HER2-Positive Breast Cancer With Brain Metastases
Dekker, Tim Johannes Adrianus
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03) : 251 - +
[38] Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
Guarneri, V.
Dieci, M. V.
Barbieri, E.
Piacentini, F.
Omarini, C.
Ficarra, G.
Bettelli, S.
Conte, P. F.
ANNALS OF ONCOLOGY, 2013, 24 (12) : 2990 - 2994
[39] Brain metastases from HER2-positive breast cancer
Susheela, Sridhar Papaiah
Revannasiddaiah, Swaroop
Madhusudhan, N.
Basavalingaiah, Ajaikumar
LANCET ONCOLOGY, 2013, 14 (01): : E3 - E3
[40] Dual HER2 blockade in adjuvant and neoadjuvant treatment of HER2-positive breast cancer: the role of pertuzumab
Duchnowska, Renata
ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 43 - 47

← 1 2 3 4 5 →